"If this works the way we think it's going to work, it will change medical practice."
I spoke with Bob Proulx, Chairman and CEO of Imagion Biosystems.
Imagion are blazing a trail in the world of imaging with their fascinating technology, which utilises nanoparticles to help detect cancer with better specificity and sensitivity, without exposure to radiation.
In our conversation, we covered the technology, what it's like to be classed as an FDA 'breakthrough' device and what the future holds for Imagion and the imaging market in general.
If you'd like to see more content like this, please visit my consultant page. You can also get in touch with me to talk about the podcast at Cameron.Ramsden@medical-cm.com.
If you'd like to get involved in the conversation, email us at cmconversations@charltonmorris.com.
Recommended.
-
05 June 2023Putting Digital Pathology Front of Mind in Medical Imaging.
The digital pathology sector has seen a great focus within medical imaging in recent years. The use of digital technologies, advanced technology and AI integration means trends are shifting. These companies are leading the way.
-
21 November 2022Career Progression for Women in STEM.
In this episode, Ellen catches up with Laura Piila, VP of Devices at Optomed. Touching on the challenges she has faced as a woman in STEM, securing FDA approval in MedTech and loads more.
-
.jpg)
11 November 2022Four Recruitment Lessons for RSNA.
Ahead of RSNA, I thought I would look back at some of the things I’ve learned from those conversations in sales, marketing, leadership, and technical recruitment over the years. Click to find out.
Comments.